LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 323

Search options

  1. Book ; Online ; E-Book: Schottenfeld and Fraumeni cancer epidemiology and prevention

    Thun, Michael J. / Linet, Martha S. / Cerhan, James R. / Haiman, Christopher A. / Schottenfeld, David

    2018  

    Title variant Cancer epidemiology and prevention
    Author's details lead editor Michael J. Thun, MD, MS ; co-editors Martha S. Linet, MD, MPH; James R. Cerhan, MD, PHD; Christopher A. Haiman, SCD; David Schottenfeld, MD, MSC ; project manager Annelie M. Landgren, MPH, PMP
    Keywords Cancer/Prevention ; Cancer/Epidemiology
    Subject code 616.994
    Language English
    Size 1 Online-Ressource (xix, 1308 Seiten), Illustrationen, Diagramme
    Edition Fourth edition
    Publisher Oxford University Press
    Publishing place New York, NY
    Publishing country United States
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT019665929
    ISBN 978-0-19-023867-4 ; 9780190238667 ; 0-19-023867-4 ; 0190238666
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  2. Article ; Online: Uncovering the Genetic Etiology of the (Posttherapy) Broken Heart.

    Linet, Martha S / Dores, Graça M / Savage, Sharon A

    Journal of the National Cancer Institute

    2022  Volume 114, Issue 8, Page(s) 1054–1056

    MeSH term(s) Cancer Survivors ; Child ; Heart ; Heart Diseases ; Humans ; Neoplasms
    Language English
    Publishing date 2022-06-07
    Publishing country United States
    Document type Editorial ; Research Support, N.I.H., Intramural ; Comment
    ZDB-ID 2992-0
    ISSN 1460-2105 ; 0027-8874 ; 0198-0157
    ISSN (online) 1460-2105
    ISSN 0027-8874 ; 0198-0157
    DOI 10.1093/jnci/djac116
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Risks of therapy-related hematologic neoplasms beyond myelodysplastic syndromes and acute myeloid leukemia.

    Dores, Graça M / Linet, Martha S / Curtis, Rochelle E / Morton, Lindsay M

    Blood

    2022  Volume 141, Issue 8, Page(s) 951–955

    MeSH term(s) Humans ; Leukemia, Myeloid, Acute ; Myelodysplastic Syndromes ; Neoplasms, Second Primary ; Hematologic Neoplasms
    Language English
    Publishing date 2022-11-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2022018051
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: The Need for a Broad-based Introduction to Radiation Science within U.S. Medical Schools' Educational Curriculum.

    Linet, Martha S / Davis, Pamela B / Brink, James A

    Radiology

    2021  Volume 301, Issue 1, Page(s) 35–40

    MeSH term(s) Curriculum ; Humans ; Radiology/education ; Schools, Medical ; United States
    Language English
    Publishing date 2021-07-20
    Publishing country United States
    Document type Editorial ; Research Support, N.I.H., Intramural
    ZDB-ID 80324-8
    ISSN 1527-1315 ; 0033-8419
    ISSN (online) 1527-1315
    ISSN 0033-8419
    DOI 10.1148/radiol.2021210665
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001-2019.

    Linet, Martha S / Curtis, Rochelle E / Schonfeld, Sara J / Vo, Jacqueline B / Morton, Lindsay M / Dores, Graça M

    EClinicalMedicine

    2024  Volume 71, Page(s) 102549

    Abstract: ... Chemotherapy-treated U.S. adults with AML have notable differences in survival by age, race and ethnicity, sex ... long-term outcomes among most treated groups.: Funding: Intramural Research Program of the U.S ... the U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Surveillance ...

    Abstract Background: Population-based survival studies of adult acute myeloid leukemia (AML) have not simultaneously evaluated age at diagnosis, race and ethnicity, sex, calendar period or AML subtypes/subgroups among chemotherapy-treated patients.
    Methods: For 28,473 chemotherapy-treated AML patients diagnosed at ages ≥20 years in population-based cancer registry areas of the Surveillance, Epidemiology, and End Results Program (2001-2018, followed through 2019), we evaluated 1-month through 5-year relative survival (RS) and 95% confidence intervals (95% CI) using the actuarial method in the SEER∗Stat Survival Session and overall survival (OS) using multivariable Cox regression to estimate proportional hazard ratios (HR) and 95% CI.
    Findings: RS decreased with increasing age (20-39, 40-59, 60-74, 75-84, ≥85 years) at AML diagnosis. RS declined substantially within the first month and, except for acute promyelocytic leukemia, decreasing patterns continued thereafter for core binding factor AML, AML with antecedent condition/therapy, and all other AML. For all ages, acute promyelocytic leukemia RS stabilized after the first year. For total AML the hazard of death was significantly increased for non-Hispanic (NH)-Black (HR = 1.18, 95% CI = 1.12-1.24) and NH-Pacific Islander patients (HR = 1.31, 95% CI = 1.11-1.55) compared with NH-White patients. In contrast, NH-Asian and Hispanic patients had similar OS to NH-White patients across all ages and most AML subgroups. Males had significantly inferior survival to females with some exceptions. Compared to 2001-2006, in 2013-2018 OS improved for all age and AML subgroups.
    Interpretation: Chemotherapy-treated U.S. adults with AML have notable differences in survival by age, race and ethnicity, sex, calendar-year period, and AML subgroup. Despite survival gains over time, our findings highlight the need for improving early outcomes across all AML subgroups, older ages, and Black and Pacific Islander patients and long-term outcomes among most treated groups.
    Funding: Intramural Research Program of the U.S. National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics, and the U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology.
    Language English
    Publishing date 2024-03-16
    Publishing country England
    Document type Journal Article
    ISSN 2589-5370
    ISSN (online) 2589-5370
    DOI 10.1016/j.eclinm.2024.102549
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: In Memoriam: Patricia A. Buffler, PhD, MPH, CPH 1938-2013.

    Linet, Martha S

    Journal of occupational and environmental medicine

    2014  Volume 56, Issue 6, Page(s) e43

    MeSH term(s) Epidemiology/history ; History, 20th Century ; History, 21st Century ; National Institute of Environmental Health Sciences (U.S.) ; Public Health Administration/history ; United States
    Language English
    Publishing date 2014-06
    Publishing country United States
    Document type Biography ; Editorial ; Historical Article
    ZDB-ID 1223932-x
    ISSN 1536-5948 ; 1076-2752
    ISSN (online) 1536-5948
    ISSN 1076-2752
    DOI 10.1097/JOM.0000000000000205
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Cause-specific mortality following polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the US population, 2001-2017.

    Dores, Graça M / Curtis, Rochelle E / Linet, Martha S / Morton, Lindsay M

    American journal of hematology

    2021  Volume 96, Issue 12, Page(s) E451–E454

    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Cause of Death ; Female ; Humans ; Male ; Middle Aged ; Polycythemia Vera/epidemiology ; Polycythemia Vera/mortality ; Primary Myelofibrosis/epidemiology ; Primary Myelofibrosis/mortality ; Thrombocythemia, Essential/epidemiology ; Thrombocythemia, Essential/mortality ; United States/epidemiology ; Young Adult
    Language English
    Publishing date 2021-10-11
    Publishing country United States
    Document type Letter ; Research Support, N.I.H., Intramural
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.26362
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Occupational radiation dose trends in U.S. radiologic technologists assisting with fluoroscopically-guided interventional procedures, 1980-2020.

    Milder, Cato M / Borrego, David / Preston, Dale L / Villoing, Daphnée / Kwon, Tae-Eun / Miller, Donald L / Alexander, Bruce H / Linet, Martha S / Lee, Choonsik / Kitahara, Cari M

    Journal of vascular and interventional radiology : JVIR

    2024  

    Abstract: Purpose: To summarize dose trends from 1980-2020 for 19,651 U.S. radiologic technologists ... reference depth ("doses") during 1980-2020 for 43,823 participants of the U.S. Radiologic Technologists ...

    Abstract Purpose: To summarize dose trends from 1980-2020 for 19,651 U.S. radiologic technologists who reported assisting with fluoroscopically-guided interventional procedures (FGIP), overall and by work history characteristics.
    Methods: We summarized 762,310 annual personal dose equivalents at a 10 mm-reference depth ("doses") during 1980-2020 for 43,823 participants of the U.S. Radiologic Technologists (USRT) cohort who responded to work history questionnaires administered during 2012-2014. This population included 19,651 technologists who reported assisting with FGIP (≥1 time per month for ≥12 consecutive months) at any time during the study period. We estimated doses corresponding to assistance with FGIP by proximity to patients, monthly procedure frequency, and procedure type. We used box plots and summary statistics (e.g., median, percentiles) to describe annual doses and dose trends.
    Results: Median annual dose corresponding to assistance with FGIP was 0.65 mSv, [interquartile range (IQR)=0.60-1.40; 95
    Conclusion: Occupational doses corresponding to assistance with FGIP were generally low but varied with exposure frequency, procedure type, and proximity to patients. These results highlight the need for vigilant dose monitoring, radiation safety training, and proper protective equipment.
    Language English
    Publishing date 2024-04-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1137756-2
    ISSN 1535-7732 ; 1051-0443
    ISSN (online) 1535-7732
    ISSN 1051-0443
    DOI 10.1016/j.jvir.2024.03.032
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Trends in risk for therapy-related myelodysplastic syndrome/acute myeloid leukemia after initial chemo/immunotherapy for common and rare lymphoid neoplasms, 2000-2018.

    Morton, Lindsay M / Curtis, Rochelle E / Linet, Martha S / Schonfeld, Sara J / Advani, Pragati G / Dalal, Nicole H / Sasse, Elizabeth C / Dores, Graça M

    EClinicalMedicine

    2023  Volume 61, Page(s) 102060

    Abstract: Background: Historically, survivors of common lymphoid neoplasms (LNs) had increased risks for therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML). Despite major treatment advances in the treatment of LNs over the last two decades, ...

    Abstract Background: Historically, survivors of common lymphoid neoplasms (LNs) had increased risks for therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML). Despite major treatment advances in the treatment of LNs over the last two decades, a comprehensive evaluation of tMDS/AML trends following both common and rare LNs treated in this contemporary period is lacking.
    Methods: In US cancer registries during 2000-2018, we identified 1496 tMDS/AML cases among 186,503 adults who were treated with initial chemo/immunotherapy for first primary LN and survived ≥1 year. We quantified tMDS/AML standardized incidence ratios (SIRs), excess absolute risks (EARs, per 10,000 person-years), and cumulative incidence.
    Findings: The highest tMDS/AML risks occurred after precursor leukemia/lymphoma (SIR = 39, EAR = 30), Burkitt leukemia/lymphoma (SIR = 20, EAR = 24), peripheral T-cell lymphoma (SIR = 12, EAR = 23), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; SIR = 9.0, EAR = 27), and mantle cell lymphoma (SIR = 8.5, EAR = 25). Elevated risks (SIRs = 4.2-6.9, EARs = 4.9-15) also were observed after all other LN subtypes except hairy cell leukemia and mycosis fungoides/Sézary syndrome. Among patients treated more recently, tMDS/AML risks were significantly higher after CLL/SLL (SIR
    Interpretation: Although tMDS/AML risks are significantly elevated after initial chemo/immunotherapy for most LNs, patients treated more recently have lower tMDS/AML risks, except after CLL/SLL. Though rare, the poor prognosis following tMDS/AML emphasizes the importance of continued efforts to reduce treatment-associated toxicity.
    Funding: This research was supported in part by the Intramural Research Program of the National Cancer Institute, National Institutes of Health. LMM, GMD, REC, and CBS verified the data, and all authors had access to the data and made the decision to submit for publication.
    Language English
    Publishing date 2023-07-05
    Publishing country England
    Document type Journal Article
    ISSN 2589-5370
    ISSN (online) 2589-5370
    DOI 10.1016/j.eclinm.2023.102060
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Book: The leukemias

    Linet, Martha S.

    epidemiologic aspects

    (Monographs in epidemiology and biostatistics ; 6)

    1985  

    Author's details Martha S. Linet
    Series title Monographs in epidemiology and biostatistics ; 6
    Collection
    Keywords Leukemia / epidemiology ; Leukemia / mortality ; Leukämie ; Epidemiologie
    Subject Krankheitsverbreitung ; Blutkrebs
    Size XIV, 293 S. : graph. Darst.
    Publisher Oxford Univ. Pr
    Publishing place New York u.a.
    Publishing country Great Britain
    Document type Book
    HBZ-ID HT002151321
    ISBN 0-19-503448-1 ; 978-0-19-503448-6
    Database Catalogue ZB MED Medicine, Health

    Kategorien

To top